Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury

Conditions

Acute Kidney Injury

Keywords

Kidney Renal

Brief summary

The purpose of this study is to collect blood and urine samples that may help identify and validate biomarkers for the early detection and risk assessment of acute kidney injury (AKI).

Kane-Gill SL, Ostermann M, Shi J, Joyce EL, Kellum JA.

2019-10-0129 citations

10.1007/s40264-019-00846-x

Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers

Eric A. J. Hoste, Peter A. McCullough, Kianoush Kashani, Lakhmir S. Chawla, Michael Joannidis et al. (12 authors)

Nephrology Dialysis Transplantation2014-09-18280 citations

10.1093/ndt/gfu292

Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmelé T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA.

2013-02-06918 citations

10.1186/cc12503

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

No

Inclusion criteria

Males and females 21 years of age or older; Subjects enrolled (first sample collection) from ED or Floor admitted to the ICU within 24 hours of enrollment; Subjects enrolled from ICU admitted to the ICU within the 24 hours prior to enrollment; Expected to remain in the ICU for at least 48 hours after enrollment; Use of indwelling urinary catheter as standard care expected for at least 48 hours after enrollment; At least one of the following acute conditions within 24 hours prior to enrollment: (Respiratory SOFA score of ≥ 2 (PaO2/FiO2 \<300)and/or Cardiovascular SOFA score of ≥ 1 (MAP \< 70 mm Hg and/or any vasopressor required). Patient (or authorized representative) able and willing to provide written informed consent for study participation.

Exclusion criteria

Special populations including women with known pregnancy, prisoners or institutionalized individuals;Previous renal transplantation;Known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria. Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment; Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic);Patient meets any of the following:Active bleeding with an anticipated need for \> 4 units PRBC;Hemoglobin \< 7 g/dL;Any other condition that in the physician's opinion would contraindicate drawing serial blood samples for clinical study purposes.

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of Novel Biomarkers From Acutely ill Patients at Risk for AKI.	10/2010 to 2/2013	Primary outcome measure: Identification and Validation of Biomarkers from Acutely ill patients at risk for AKI. (N=744) Secondary outcomes including follow-up (N=890).

Countries

Austria, Canada, France, Germany, Spain, Sweden, United Kingdom, United States

Outcome results